Spontaneous Diabetes in Hemizygous Human Amylin Transgenic Mice That Developed Neither Islet Amyloid nor Peripheral Insulin Resistance by Wong, Winifred P.S. et al.
Spontaneous Diabetes in Hemizygous Human Amylin
Transgenic Mice That Developed Neither Islet Amyloid
nor Peripheral Insulin Resistance
Winifred P.S. Wong,
1 David W. Scott,
1 Chia-Lin Chuang,
1 Shaoping Zhang,
1,2 Hong Liu,
1
Athena Ferreira,
1 Etuate L. Saaﬁ,
1 Yee Soon Choong,
1 and Garth J.S. Cooper
1,2,3
OBJECTIVES—We sought to 1) Determine whether soluble-
misfolded amylin or insoluble-ﬁbrillar amylin may cause or result
from diabetes in human amylin transgenic mice and 2) deter-
mine the role, if any, that insulin resistance might play in these
processes.
RESEARCH DESIGN AND METHODS—We characterized the
phenotypes of independent transgenic mouse lines that display
pancreas-speciﬁc expression of human amylin or a nonaggregat-
ing homolog, [
25,28,29Pro]human amylin, in an FVB/n background.
RESULTS—Diabetes occurred in hemizygous human amylin
transgenic mice from 6 weeks after birth. Glucose tolerance was
impaired during the mid- and end-diabetic phases, in which
progressive -cell loss paralleled decreasing pancreatic and
plasma insulin and amylin. Peripheral insulin resistance was
absent because glucose uptake rates were equivalent in isolated
soleus muscles from transgenic and control animals. Even in
advanced diabetes, islets lacked amyloid deposits. In islets from
nontransgenic mice, glucagon and somatostatin cells were
present mainly at the periphery and insulin cells were mainly in
the core; in contrast, all three cell types were distributed
throughout the islet in transgenic animals. [
25,28,29Pro]human
amylin transgenic mice developed neither -cell degeneration nor
glucose intolerance.
CONCLUSIONS—Overexpression of ﬁbrillogenic human amy-
lin in these human amylin transgenic mice caused -cell degen-
eration and diabetes through mechanisms independent from
both peripheral insulin resistance and islet amyloid. These ﬁnd-
ings are consistent with -cell death evoked by misfolded but
soluble cytotoxic species, such as those formed by human amylin
in vitro. Diabetes 57:2737–2744, 2008
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ncreasing evidence indicates that decreased -cell
mass contributes to the impaired insulin secretion
characteristic of type 2 diabetes (1–3). Amylin, also
referred to as islet amyloid polypeptide, is a 37-
amino acid polypeptide (4,5) secreted from pancreatic
islet -cells whose aggregation results in islet amyloid
formation in type 2 diabetes (6). Islet amyloid has been
reported in 40–90% of pancreases from type 2 diabetic
subjects studied post mortem (7–11) and has been linked
to both decreased -cell mass and -cell dysfunction
(12,13). In vitro, human amylin causes apoptosis of islet
-cells, and there is growing evidence that this pathogenic
process may contribute to the -cell deﬁcit in type 2
diabetes (1,2,14,15). However, it remains unresolved
whether islet amyloid contributes to the etiopathogenesis
of type 2 diabetes or, by contrast, occurs only as a
consequence of the disease.
Several independent lines of human amylin transgenic
mice have been developed to investigate the role of amylin
and islet amyloid in the pathogenesis of type 2 diabetes
(16–19). The ﬁndings and conclusions from phenotypic
characterization studies are wide ranging and sometimes
at variance. Transgenic animals developed by several
research groups did not develop spontaneous diabetes or
insulin resistance or exhibit evidence of islet amyloid
formation, suggesting that overexpression of human amy-
lin alone was not sufﬁcient to contribute to diabetes
development and islet amyloid formation in those models
(16–18). In contrast, Janson et al. (19) showed develop-
ment of spontaneous diabetes in the absence of islet
amyloid in homozygous individuals from a further trans-
genic mouse model, consistent with the view that overex-
pression of human amylin is sufﬁcient for diabetes
development but not islet amyloid formation in that
model. It was previously thought that overexpression of
human amylin might be sufﬁcient for islet amyloid forma-
tion, but some studies have suggested that insulin resis-
tance might also be necessary (20–22).
Evidence concerning the role of human amylin in the
processes that lead to or cause diabetes remains conﬂict-
ing, and a clear role for human amylin–mediated -cell
death has not been established at this time, at least in part
due to conﬂicting evidence from the different lines of
human amylin transgenic mice. Previous reports have
described the noticeable lack of correlation between amy-
loid deposition and hyperglycemia in other transgenic
models of amylin-induced diabetes (21,23). Islets from
homozygous individuals from the FVB/n-based line re-
ported by Janson et al. (19) demonstrated a pattern of
-cell loss that closely reﬂects that in islets from human
type 2 diabetic patients (1,3,9), but hemizygous animals
from that line reportedly do not develop diabetes.
Here, we report a transgenic human amylin mouse
model (L13) in which hemizygous individuals developed
early-onset diabetes without peripheral insulin resistance
and islet amyloid formation. We demonstrate that the
disappearance of functional -cells during the progression
of diabetes in this model contributes to the pathogenesis
of diabetes. The absence of islet amyloid in the pancreas of
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DIABETES, VOL. 57, OCTOBER 2008 2737transgenic mice before diabetes onset and during its
progression, despite the high secretion rates of human
amylin, shows that islet amyloid is not required for islet
-cell degeneration and loss of physiological insulin secre-
tion. These ﬁndings are consistent with the reports of
Janson et al. (19) and provide strong support for continu-
ing exploration of the mechanism by which human amylin
evokes -cell death and contributes to the failure of insulin
secretion in type 2 diabetes.
RESEARCH DESIGN AND METHODS
Generation of transgenic lines. Lines of human amylin transgenic mice
were developed in a FVB/n genetic background through pronuclear microin-
jection of the following transgenic construct into fertilized oocytes.
The transgene construct consisted of a RT-PCR–generated human amylin
cDNA under the regulatory control of the rat insulin-II promoter. Two lines
(L13 and L9) were found to develop spontaneous diabetes. One of these, L13,
was selected for intensive characterization and is that which is mainly
described in this paper. Southern blotting of genomic DNA demonstrated that
L13 hemizygous mice have 36  7 copies of the transgene. Pancreas-speciﬁc
expression of human amylin was conﬁrmed by Northern blotting analysis of
RNA transcripts from various organs.
[
25,28,29Pro]human amylin transgenic mice (L44) were generated in the
FVB/n strain, as was L13, using a similar transgene construct with the
wild-type human amylin cDNA replaced by a [
25,28,29Pro]human amylin cDNA.
The modiﬁed human amylin variant has proline residues at positions 25, 28,
and 29. This nonamyloidogenic human amylin transgenic line was generated
to provide a control to monitor the nonspeciﬁc effects of overexpression of a
peptide within islet -cells. Pancreas-speciﬁc expression of [
25,28,29Pro]human
amylin was conﬁrmed by Northern blotting and immunohistochemical analy-
sis (results not shown).
Experimental design. Hemizygous L13 and L44 male animals were back-
crossed with wild-type FVB/n females. Hemizygous male offspring were
selected for this study, and nontransgenic male littermates were used as
controls. Animals from L13 were divided into three groups based on weekly
nonfasted blood glucose reading: pre-diabetic, mid-diabetic, and end-diabetic
phases. Control animals and those from L44 were analyzed at similar time
points. L13 animals that were normoglycemic at 3 and 4 weeks of age and
those that had been hyperglycemic for 5 consecutive weeks were categorized
into the pre- and mid-diabetic groups, respectively. End-diabetic animals were
at the terminal stages of diabetes and displayed loss of exploratory behavior,
relative immobility, and failure to groom. All animal experiments were
approved by the institution’s animal ethics committee.
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FIG. 1. Time-dependent changes in blood glucose and frequency of
diabetes onset in human amylin transgenic mice. A: Blood glucose
concentrations in human amylin transgenic mice (E, n  51), matched
nontransgenic controls (F, n  49), and [
25,28,29Pro]human amylin
transgenic mice (f, n  4). B: Frequency of diabetes occurrence in the
human amylin transgenic mice. Diabetes incidence peaked between 6
and 12 weeks of age, and cumulative incidence was 96%. **P < 0.01,
***P < 0.001 for human amylin transgenic vs. nontransgenic mice.
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FIG. 2. Glucose tolerance, insulin tolerance, and muscle glucose uptake
during diabetes progression in human amylin transgenic mice. A:
IPGTT in human amylin transgenic (E, n  18), [
25,28,29Pro]human
amylin transgenic (, n  4), and nontransgenic control (F, n  16)
mice. B: IPITT in human amylin transgenic (E, n  15) and nontrans-
genic littermates (F, n  14). C: In vitro glucose uptake in soleus
muscles incubated without (basal) and with 2 mU/ml insulin in fasted
human amylin transgenic (f, n  7) and nontransgenic controls (,
n  7). *P < 0.05, **P < 0.01, and ***P < 0.001.
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administered into the intraperitoneal cavity (1g/kg body wt). Blood glucose
was determined using a glucose meter (Roche Diagnostics) before injection
and at 5, 15, 30, 60, 90, and 120 min after injection. The procedure for the
insulin tolerance test (ITT) was identical to that of the glucose tolerance test
(GTT) with the exception that soluble insulin (Novo Nordisk Pharmaceuti-
cals) was injected into the intraperitoneal cavity (1 mU/g body wt) after a 4-h
fast.
Muscle glucose uptake assay. Soleus muscles were ﬁrst preincubated for 30
min in Krebs-Henseleit bicarbonate buffer (KHB) supplemented with 8 mmol/l
glucose and 32 mmol/l D-mannitol with or without 2 mU/ml insulin. Muscles
were then rinsed and incubated in KHB buffer with 2 Ci/ml [
3H]2-deoxyglu-
cose (ICN Pharmaceuticals), 0.3 Ci/ml [
14C]D-mannitol (ICN Pharmaceuti-
cals), and 2 mmol/l sodium pyruvate for 30 min. All incubations were
performed under 95% O2/5% CO2 with gentle agitation at 30°C followed by
processing. Muscles were boiled (1 mol/l NaOH, 10 min), and muscle extracts
were neutralized with 5 mol/l HCl. Radioactivity of muscle extracts and
incubation media was determined in duplicates for dual labels.
Pancreatic protein analysis. Total protein was extracted from frozen
pancreatic tissue by acid-ethanol (1.5% HCl, 75% ethanol, and 20 l/mg
pancreatic wt). After overnight incubation (4°C on shaking), homogenates
were centrifuged, supernatant was removed, and pancreatic extracts were
neutralized (pH 7) with 1 mol/l Tris base. Total pancreatic protein was
quantiﬁed using BCA assay (Sigma-Aldrich).
Hormone measurements. Immunoreactive insulin (Mercodia) and human
amylin (Linco Research) were measured in plasma and pancreatic extracts
using enzyme-linked immunosorbent assays (ELISAs). Total amylin (Penin-
sula Laboratories) and glucagon (Linco Research) were determined using
radioimmunoassay (RIA) kits. Somatostatin was measured using an enzyme
immunosorbent assay kit (Phoenix Pharmaceutical). All kits were used
according to manufacturers’ instructions.
Immunohistochemical and morphometric analyses. Pancreatic tissues
were ﬁxed in 4% paraformaldehyde, embedded in parafﬁn, and sectioned at 7
m. Serial sections were stained with Congo red. Amyloid-positive pancreatic
sections were included with every Congo red staining run as positive controls.
Sections were also immunostained with anti-glucagon (ICN Pharmaceuticals),
anti-insulin (Dako), anti-amylin (in-house derived), and/or anti-somatostatin
(Santa Cruz Biotechnology) antibodies. Appropriate second antibodies con-
jugated to ﬂuorescein isothiocyanate, Rhodamine Red, or Cy5 (Jackson
ImmunoResearch Laboratories) were used for the covisualization of -, -,
and -cells within the islets (TCS SP2; Leica Microsystems). Cross-sectional
islet areas and total pancreatic section areas were determined in hematoxylin-
eosin sections under light microscopy using image analyses software (Axio-
Vision 2; Carl Zeiss). -Cell mass was estimated using a previously described
method (24).
For immunoﬂuorescence staining for cleaved caspase-3, pancreatic tissues
were immediately frozen and embedded in OCT. Eight-micrometer sections
were cut and initially blocked with 10% (vol/vol) normal goat serum for 2 h
and then incubated with rabbit anti–cleaved caspase-3 (Cell Signaling)
followed by detection using goat anti-rabbit Rhodamine Red-X–conjugated
secondary antibody (Jackson ImmunoResearch Laboratories). Stained sec-
tions were viewed and photographed using inverted-phase ﬂuorescence
microscopy (Nikon).
Transmission electron microscopy. Pancreases were cut into 1-mm
3 pieces
and ﬁxed in 2% glutaraldehyde and 0.1 mol/l Sorenson’s phosphate buffer (pH
7.2, 4°C, overnight). Specimens were postﬁxed with 0.1% osmium tetroxide
and 0.1 mol/l Sorenson’s phosphate buffer (pH 7.2, 1 h), followed by dehydra-
tion in increasing concentrations of ethanol solutions. Specimens were then
inﬁltrated with a 1:1 mixture of epoxy resin and 100% ethanol (1 h, room
temperature) followed by 100% epoxy resin inﬁltration overnight. Specimens
were then embedded with fresh resin and cured (48 h, 60°C). Ultrathin
sections were collected onto 200-mesh copper grids and double stained with
2% (wt/vol) aqueous uranyl acetate followed by lead citrate before viewing
(CM-12; Phillips).
Statistical analyses. All data are expressed as means  SE. Independent
sample t tests were performed using SPSS v11.5. Two-way ANOVA, general
linear model, and post hoc Tukey’s honestly signiﬁcant difference analyses
were performed using Statistica 6.0. P values 0.05 were accepted as
statistically signiﬁcant.
RESULTS
Overexpression of human amylin leads to diabetes
and glucose intolerance. Hemizygous human amylin
transgenic mice developed hyperglycemia from 6 weeks
after birth (Fig. 1A), from which time blood glucose values
were elevated compared with controls (P  0.01). Blood
glucose remained signiﬁcantly elevated throughout the
entire 31-week monitoring period (Fig. 1A). Ninety-six
percent of the transgenic mice developed diabetes during
this monitoring period, with a mean onset time of 11.2
weeks (Fig. 1B). Intraperitoneal GTTs (IPGTTs) per-
formed in fasted animals at the mid-diabetic stage (Fig.
2A) demonstrated impaired glucose tolerance and ele-
TABLE 1
Pancreatic hormone levels at pre-, mid-, and end-diabetic stages in L13 human amylin transgenic, nontransgenic, and L44

25,28,29Pro	human amylin transgenic (tritransgenic) mice
Stage of diabetes
Pre-diabetic Mid-diabetic End-diabetic
Insulin
Nontransgenic 160.6  57.7 826.3  162.7 718.8  120.7
Transgenic 371.1  99.7 195.8  93.6* 21.3  5.7†
Tritransgenic 746.7  319.0* 2,509.4  775.3*‡ 2,675.3  103.7†‡
Total amylin
Nontransgenic 50.7  5.2 78.2  3.9 80.2  6.6
Transgenic 128.8  23.2* 27.8  9.7† 5.2  0.6†
Tritransgenic 318.1  77.6†§ 836.0  17.0*‡ 1,520.9  505.9†‡
Human amylin
Nontransgenic 0.05  0.00 0.05  0.00 0.05  0.00
Transgenic 14.3  3.5† 7.3  2.7¶ 0.3  0.1†
Mouse amylin
Nontransgenic 50.7  5.2 78.2  3.9 80.2  6.6
Transgenic 114.6  19.9* 20.5  7.0† 4.9  0.6†
Glucagon
Nontransgenic 33.8  3.4 27.4  3.7 22.6  1.7
Transgenic 38.5  6.0 27.9  3.4 32.4  4.0¶
Somatostatin
Nontransgenic 5.2  0.9 8.0  0.7 6.4  0.4
Transgenic 4.7  0.9 6.9  1.0 6.5  0.9
Data are means  SE. Hormone measurements (pmol/mg pancreatic protein) were normalized to total pancreatic protein before statistical
analyses. *P  0.01, †P  0.001, and ¶P  0.05 vs. nontransgenic; ‡P  0.001 and §P  0.01 vs. transgenic; n 
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transgenic mice (P  0.05). The lack of glucose-stimulated
insulin secretion during GTT present in human amylin
transgenic mice (t0 29.9  15.1 cf. t15 39.1  18.5 pmol/l;
NS), is consistent with impaired -cell function. In con-
trast, we detected a positive insulin response to glucose in
the control nontransgenic mice (t0 26.2  4.3 cf. t15 128.6 
55.7 pmol/l; P  0.05). Neither fasting hyperglycemia nor
impaired glucose tolerance was present in [
25,28,29Pro]hu-
man amylin transgenic mice (Fig. 2A), wherein blood
glucose concentrations remained equivalent to control
levels at all times during the observation period (from
birth to 24 weeks of age) (Fig. 1A).
Systemic insulin administration (intraperitoneal ITT [IP-
ITT]) at the mid-diabetic stage (Fig. 2B) showed that
human amylin transgenic mice were more responsive to
insulin, consistent with the absence of peripheral insulin
resistance (P  0.01). Absence of peripheral insulin resis-
tance in human amylin transgenic mice was conﬁrmed by
ex vivo glucose uptake analysis in isolated, stripped soleus
muscles (Fig. 2C), which showed similar rates of glucose
uptake between transgenic and nontransgenic animals in
either the basal or the insulin-stimulated states. This
ﬁnding is consistent with that from the ITT analysis and
conﬁrms that peripheral insulin resistance is not impli-
cated in the pathogenesis of diabetes in this model.
Human amylin overexpression leads to decreased
islet function. Plasma and pancreatic hormone levels
were determined at the pre-diabetic, mid-diabetic, and
end-diabetic phases and at equivalent times in nondiabetic
mice. Elevated pancreatic human amylin (P  0.001) and,
hence, total amylin (P  0.01) was present before diabetes
developed (Table 1). The development of diabetes in these
mice (at the mid- and end-diabetic stages) was associated
with concomitant decrements in pancreatic -cell hor-
mones: insulin (P  0.01) and total amylin (P  0.001). By
contrast, in [
25,28,29Pro]human amylin transgenic mice,
which did not develop diabetes, the pancreatic total amy-
lin and insulin levels were signiﬁcantly higher than in
nondiabetic animals at all three phases (Table 1). This
suggests that overexpression of human amylin results in
-cell destruction and impairment of -cell function,
which is consistent with our histological evidence of -cell
loss during diabetes progression (Fig. 3A–F). The decrease
in -cell mass in human amylin transgenic mice (Fig. 3H)
conﬁrms that the loss of -cell mass contributes to the
mechanism of diabetes in these human amylin mice, at
least in part. Pancreatic glucagon was also elevated at
the end-diabetic stage in transgenic animals (P  0.05),
whereas no signiﬁcant alteration in pancreatic somatosta-
tin was observed (Table 1).
Plasma hormone concentrations also showed responses
similar to those of their respective pancreatic contents
(Table 2). As expected, human amylin was detected in
plasma of transgenic animals only (at the pre-, mid-, and
end-diabetic phases; P  0.05 in each case). At the
end-diabetic stage, plasma insulin was decreased in trans-
genic mice (P  0.05); by contrast, increased plasma
glucagon was observed in transgenic animals at this stage
(P  0.001). Plasma total amylin and somatostatin could
not be determined because of insufﬁcient sample volumes.
The speciﬁcity of the amylin assay systems used in this
study enabled us to calculate estimated values for pancre-
atic mouse amylin by subtraction of values for pancreatic
human amylin from corresponding measurements of total
pancreatic amylin (Table 1). Both the total amylin RIA and
the human amylin ELISA systems were validated to con-
ﬁrm that antibodies in each recognized the appropriate
amylin species. Our validation experiments demonstrated
FIG. 3. Expression patterns of insulin, glucagon, and somatostatin and
quantitative histomorphometric analysis in pancreatic islets from
transgenic and nontransgenic mice. Representative sections of insulin
(green), glucagon (red), and somatostatin (cyan) immunolocalization
in nontransgenic control (A, C, and E) and human amylin transgenic
(B, D, and F) mice at pre-diabetic (A and B), mid-diabetic (C and D),
and late-diabetic (E and F) stages. G: Islet hormone expression from a
late-stage [
25,28,29Pro]human amylin transgenic mouse. H: -Cell mass
analysis from human amylin transgenic and nontransgenic animals.
-Cell mass is estimated from data for the total pancreatic weight and
the relative volume (derived from percentage of the islet area) of the
-cells, as described by Bonner-Weir (24). The pancreatic weight is
equated to pancreatic volume with the reasonable assumption that 1
cm
3 tissue weighs 1 g. Results are expressed as fold changes of -cell
mass as relative to nontransgenic mice at the pre-diabetic stage, whose
numbers were set at unity.
P < 0.001, nontransgenic mid-diabetic/
end-diabetic vs. nontransgenic pre-diabetic. ***P < 0.001, transgenic
vs. nontransgenic. (Please see http://dx.doi.org/10.2337/db06-1755 for
a high-quality digital representation of this image.)
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human amylin and did not cross-react with mouse amylin
(Fig. 4A). Antibodies used in the RIA system were 100%
cross-reactive with human amylin, murine amylin, and
[
25,28,29Pro]human amylin, thus recognizing human and
murine amylin at equimolar concentrations but detecting
[
25,28,29Pro]human amylin at lower sensitivity compared
with the former (Fig. 4B). Antibodies in both assay sys-
tems also required that amylin be amidated at its COOH
terminus for recognition.
Elevated levels of mouse amylin were observed in
transgenic animals before diabetes onset (P  0.01). Thus,
overexpression of human amylin may have contributed to
the elevated production of endogenous amylin. However,
decreased pancreatic mouse amylin concentrations were
present at the mid- and end-diabetic stages in human
amylin transgenic mice, consistent with the progressive
decline in -cell function that occurred during the course
of diabetes progression in these animals.
Abnormal islet architecture in the absence of islet
amyloid formation. Immuno-labelling of -, -, and
-cells at the end-diabetic stage showed markedly de-
creased -cell numbers in transgenic islets, consistent
with decreased numbers of functional -cells and de-
creased insulin production in these animals (Fig. 3F).
Electron microscopic studies, in which at least 30 islets
were examined from each animal, further conﬁrmed the
presence of typical -cell secretory granules in nondia-
betic islets (Fig. 5G) that, by contrast, were largely lacking
in those -cells (deﬁned as endocrine cells present in the
body of the pancreas but lacking typical -o r-cell
granules) remaining in the body of the pancreas in human
amylin transgenic mice at the end stage (Fig. 5H).
-Cells from end-stage diabetic mice frequently showed
invagination of their nuclear membranes and chromatin
margination, both characteristics of cells undergoing apo-
ptosis (Fig. 5H). In addition, apoptosis was also detected
and quantiﬁed by immunoﬂuorescence staining for
cleaved caspase-3 (Fig. 5I and J). About 60 islets from
each study group (20 islets per animal and 3 animals per
group) were examined, and the total number of cleaved
caspase-3–positive cells was determined. Numbers of ap-
optotic islet cells were found to be signiﬁcantly increased
in the transgenic mice at the mid-diabetic stage (Fig. 5I)
compared with matched nondiabetic, nontransgenic mice
(Fig. 5K). These ﬁndings are consistent with in vitro
studies demonstrating human amylin-evoked apoptosis in
cultured -cells (15). In contrast, equivalent -cell loss was
never observed in islets of [
25,28,29Pro]human amylin trans-
genic mice, although alterations in the relative positioning
of - and -cells similar to those demonstrated in human
amylin transgenic mice were present (Fig. 3G). This latter
observation indicates that the modiﬁcations in islet cell
distribution were insufﬁcient in themselves to cause -cell
loss or defective insulin secretion.
Examination under polarized light of Congo red-stained
sections revealed the absence of green birefringence at all
three stages of the diabetic process in human amylin
transgenic mice (Fig. 5A–F). Moreover, Congo red–stained
islet amyloid was never detected in [
25,28,29Pro]human
amylin transgenic mice (data not shown). These ﬁndings
indicate that Congo red–stainable islet amyloid is not
necessary for and cannot have played a role in the
development of diabetes in this model. We note that islet
amyloid–positive sections as positive controls were in-
cluded with every Congo red staining run.
DISCUSSION
Here, we report characterization of a hemizygous line of
human amylin transgenic mice (L13) that synthesizes
human amylin in its pancreatic islets and demonstrates
increased release of human amylin into the plasma (Table
2). In the current study, 96% of L13 transgenic mice
TABLE 2
Plasma hormone levels at the pre-, mid-, and end-diabetic stages
in human amylin transgenic and nontransgenic animals
Stage of diabetes
Pre-diabetic Mid-diabetic End-diabetic
Insulin
Nontransgenic 120.5  40.4 176.2  36.8 178.4  46.9
Transgenic 78.3  21.9 104.2  31.5 10.0  5.3*
Human amylin
Nontransgenic 0.7  0.4 1.2  0.2 2.1  0.3
Transgenic 27.7  7.9† 14.9  3.8* 3.7  0.01*
Glucagon
Nontransgenic 22.6  3.1 14.0  4.3 11.9  1.5
Transgenic 33.0  7.2 15.6  3.5 43.0  5.1‡
Data are means  SE (pmol/l). *P  0.05, †P  0.01, and ‡P  0.001;
nontransgenic vs. transgenic; n 
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FIG. 4. Antibody cross-reactivity against human amylin and murine
amylin measured in ELISA (A) and RIA (B) systems. F, Human amylin;
, murine amylin; f,[
25,28,29Pro]human amylin; and E, human insulin.
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95% were diabetic by 22.5 weeks of age; by contrast,
corresponding rates of diabetes in nontransgenic litter-
mates were 0% (Fig. 1). Diabetes in L13 animals is associ-
ated with decreased -cell function (Table 1). These
animals have never been found to be hyperinsulinemic
(Table 2) but show signiﬁcant impairment of glucose
tolerance (Fig. 2A) in the absence of peripheral insulin
resistance (Fig. 2C) or islet amyloid formation (Fig. 5A–F).
L13 transgenic mice had unaltered levels of pancreatic
and plasma insulin during the pre-diabetic stage (Tables 1
and 2). Despite the lack of signiﬁcant differences in plasma
insulin between transgenic and nontransgenic mice at the
mid-diabetic stage (Table 2), a fourfold decrease in pan-
creatic insulin was present in transgenic mice during this
period (Table 1). At the end-diabetic stage, however,
17-fold decreases in pancreatic and plasma insulin were
present (Tables 1 and 2). The progressive development of
-cell dysfunction over the diabetic process was paralleled
by a progressive loss of insulin immunoreactive cells
between the mid- (Fig. 3D) and end-diabetic stages (Fig.
3F) in transgenic islets, indicating progressive falls in the
number of functional -cells in hemizygous L13 mice. The
disappearance of islet -cells with concomitant develop-
ment of impaired insulin secretion is thus responsible for
the observed diabetic phenotype in this model.
Lines of [
25,28,29Pro]human amylin transgenic mice were
also constructed to address the possible nonspeciﬁc cau-
sation of diabetes by overexpression of protein within islet
-cells. The aggregation potential of [
25,28,29Pro]human
amylin has been eliminated by substitution of three prolyl
residues at positions 25, 28, and 29 within the wild-type
human amylin molecule. Mice expressing the [
25,28,29Pro]-
human amylin transgene in their islet -cells do not
develop either islet -cell disappearance or insulin-deﬁ-
cient diabetes (Fig. 3G), demonstrating that the insertion
of this transgene and its expression in islet -cells of a
nonﬁbrillogenic amylin variant is not in itself sufﬁcient to
cause -cell destruction. Given that [
25,28,29Pro]human
amylin mice expressing a nonaggregating amylin variant
do not develop diabetes (Fig. 2A) or islet -cell degener-
ation (Fig. 3G), ﬁndings presented here support the idea
that the development of diabetes in mice expressing
wild-type human amylin (L13) is caused speciﬁcally by the
expression of a ﬁbrillogenic amylin variant in islet -cells
rather than simply a nonspeciﬁc event caused by overex-
pression of any protein from this transgene in this loca-
tion. It thus appears that the amyloidogenic property of
human amylin is necessary for its ability to cause -cell
disappearance and diabetes, just as it is for its in vitro
cytotoxicity (25,26).
Human amylin transgenic mouse models have previ-
ously been investigated by other laboratories (16–19).
Phenotypic observations reported in those mice have been
wide ranging; these have varied from a complete lack of
spontaneous diabetes (16–18) to the appearance of severe
early-onset diabetes in one line (19). The data reported
here are closest to those reported by Janson et al. (19) and
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FIG. 5. Light and electron microscopic analysis of structure and immuno-
ﬂuorescence study of apoptosis were performed in islets from represen-
tative nontransgenic (NTG) and human amylin transgenic (TG) mice.
Congo red–stained section imaged under polarized light of representative
islets from nontransgenic (A, C, and E) and transgenic (B, D, and F) mice
at pre-diabetic (A and B), mid-diabetic (C and D), and late-diabetic (E, F)
stages. Birefringence is collagenous. Magniﬁcation 400. TEM images of
islets from end-stage nontransgenic (G) and human amylin transgenic
(H) mice. G: Normal -cell insulin secretory granules with hallmark
dense cores and surrounding halos (arrowed), healthy nucleus (N), and
surrounding exocrine acini (Ea). H: Section from end-stage diabetic
human amylin transgenic mouse showing characteristic absence of
insulin secretory granules and margination of chromatin with invagi-
nation of the nuclear membrane typical of apoptosis and surrounding
exocrine acini. Ea, endocrine acini; N, nucleus. Scale bars  2 m.
Immunoﬂuorescence staining for cleaved caspase-3 in nondiabetic
nontransgenic mice (I) and mid-diabetic transgenic mice (J). K: Quan-
titative measurement of islet cell apoptosis by numeric counts of
cleaved caspase-3–positive cells. Results are expressed as fold increase
of apoptotic cells in transgenic mice compared with nontransgenic
mice, whose numbers were set at unity. ***P < 0.001 vs. nontransgenic.
(Please see http://dx.doi.org/10.2337/db06-1755 for a high-quality digi-
tal representation of this ﬁgure.)
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formation of detectable islet amyloid. However, our ﬁnd-
ings were demonstrated in hemizygous animals, whereas
those of Janson et al. (19) were reported in homozygous
mice, although it has yet to be determined whether these
two lines have comparable human amylin expression
levels. Differences in amylin expression levels are one
possible explanation for phenotypic variation between
these strains of transgenic mice.
Reported phenotypic differences between strains of
human amylin transgenic mice might also be attributable,
at least in part, to the genetics of the background strain in
which they were generated. Such transgenic mice have
mainly been developed in two genetic backgrounds,
FVB/n, in the current study and that of Janson et al. (19),
and C57BL/6J (16,18). Severe spontaneous diabetes has
previously been reported in homozygous individuals from
a line generated in the FVB/n background (19) but has
reportedly been absent in C57BL/6J-based strains (16,18).
The inﬂuence of genetic background on phenotypic out-
comes is well recognized. For example, Haluzik et al.
(2004) reported the effect of the ob/ob mutation in both
FVB/n and C57BL/6J backgrounds. Mice from the FVB/n
strain were severely hyperglycemic, had lower triglyceride
clearance, and were more insulin resistant than their
C57BL/6J counterparts (27). This implies that the FVB/n
background could be more susceptible to abnormal lipid
and glucose metabolism and thus might have a greater
predisposition to the development of diabetes. The L13
transgenic mouse model reported here was generated in
the FVB/n background and demonstrated development of
spontaneous diabetes, consistent with this hypothesis.
Previous in vitro studies are also consistent with the
idea that the cytotoxicity of amyloid-forming amylin pep-
tides, such as human amylin per se, is conferred by soluble
species rather than mature, aggregated ﬁbrils (2,25,28).
Activation of an apoptotic JNK1/c-Jun/caspase-8/caspase-3
pathway is a related downstream mechanism by which
amylin-induced destruction of islet -cells occurs in vitro
(29–31). Here, we have shown that caspase-3 activation
also occurs in pancreatic islets of L13 hemizygous mice
but not in the islets of their nontransgenic littermates; both
ﬁndings are consistent with -cell destruction through
such an apoptotic pathway in these transgenic mice.
Although both non–-cells and -cells could theoretically
have contributed to our analysis of islet cell apoptosis by
activated caspase 3 immunoﬂuorescence, we believe that
it was mostly due to -cells because of the known -cell
targeting properties of the human amylin construct used
herein and the demonstrated loss of -cells from the islets
of diabetic transgenic animals, whereas non–-cells (glu-
cagon- and somatostatin-containing) were relatively in-
creased in the islets of late-diabetic animals (Fig. 3F). In
addition, transmission electron microscopy (TEM) ﬁnd-
ings reported herein also provide structural evidence for
the occurrence of -cell apoptosis in these transgenic mice
(Fig. 5H), consistent with other reports (2,15,32).
Despite the overexpression of human amylin in pancre-
atic islet -cells, Congo red–stainable islet amyloid did not
contribute to the pathogenesis of diabetes in L13 trans-
genic mice (Fig. 5A–F). However, we cannot exclude the
possibility of a presence of small human amylin aggre-
gates/oligomers that is not detectable by Congo red stain-
ing. An absence of islet amyloid has previously been
reported in another line of human amylin transgenic mice
that develop spontaneous diabetes (19). The greater than
twofold increase in pancreatic mouse amylin observed in
L13 mice (Table 1) may play a role in the lack of islet
amyloid formation in these mice. Westermark et al. (2000)
reported that mice expressing human amylin without
murine amylin (hA
//mA

/
) developed extracellular
ﬁbrillar amyloid deposits by 12 months of age, compared
with transgenic human amylin mice (hA
//mA
/), which
had developed them by 16 months of age. The earlier onset
of islet amyloid formation in hA
//mA

/
 mice compared
with hA
//mA
/ mice was reportedly interpreted as
consistent with an inhibitory effect of mouse amylin on
ﬁbril formation (33).
In summary, islet-speciﬁc overexpression of human
amylin in L13 mice caused diabetes associated with de-
generation and loss of islet -cells with progressive im-
pairment of insulin secretion. The disease mechanism in
these mice is independent of both large islet amyloid
deposits and peripheral insulin resistance. Overexpression
of both human amylin and [
25,28,29Pro]human amylin
caused altered islet-cell type distribution, consistent with
prior reports (34). The pathophysiological relevance of
this alteration is unclear, but it may be a nonspeciﬁc effect
of overexpression of a protein in -cells and is unlikely in
itself to be causative of impaired insulin secretion. When
combined, these two lines of transgenic mice form a
composite model that may well have utility in the search
for compounds with the pharmacological properties of
ameliorating or suppressing human amylin–mediated
-cell death and type 2 diabetes evoked by human amylin–
mediated mechanisms.
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